These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

672 related items for PubMed ID: 28350519

  • 1. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
    Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P.
    J Clin Oncol; 2017 May 10; 35(14):1591-1597. PubMed ID: 28350519
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
    Zeidan AM, Al Ali NH, Padron E, Lancet J, List A, Komrokji RS.
    Clin Lymphoma Myeloma Leuk; 2015 Nov 10; 15(11):705-10. PubMed ID: 26440749
    [Abstract] [Full Text] [Related]

  • 4. Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
    Ma X, Steensma DP, Scott BL, Kiselev P, Sugrue MM, Swern AS.
    BMJ Open; 2018 Jul 23; 8(7):e019955. PubMed ID: 30037860
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.
    Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F.
    Leukemia; 2016 Apr 23; 30(4):897-905. PubMed ID: 26500139
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD.
    J Clin Oncol; 2006 Jun 01; 24(16):2576-82. PubMed ID: 16735711
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
    Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Cañizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF.
    J Hematol Oncol; 2017 Jun 26; 10(1):131. PubMed ID: 28651604
    [Abstract] [Full Text] [Related]

  • 12. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
    Arcioni F, Roncadori A, Di Battista V, Tura S, Covezzoli A, Cundari S, Mecucci C, MORE Study Centres.
    Eur J Haematol; 2018 Jul 26; 101(1):78-85. PubMed ID: 29569278
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
    Cerqui E, Pelizzari A, Schieppati F, Borlenghi E, Pagani C, Bellotti D, Lamorgese C, Boiocchi L, Sottini A, Imberti L, Rossi G.
    Leuk Lymphoma; 2015 Jul 26; 56(11):3129-34. PubMed ID: 25811676
    [Abstract] [Full Text] [Related]

  • 15. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
    Aschauer G, Greil R, Linkesch W, Nösslinger T, Stauder R, Burgstaller S, Fiegl M, Fridrik M, Girschikofsky M, Keil F, Petzer A.
    Clin Lymphoma Myeloma Leuk; 2015 Nov 26; 15(11):e143-9. PubMed ID: 26422252
    [Abstract] [Full Text] [Related]

  • 16. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
    Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA, Backstrom J, Glasmacher A, Hasford J, Germing U, International Working Group on MDS with del(5q).
    Leukemia; 2013 Apr 26; 27(5):1072-9. PubMed ID: 23257782
    [Abstract] [Full Text] [Related]

  • 17. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
    Stahl M, Zeidan AM.
    Cancer; 2017 May 15; 123(10):1703-1713. PubMed ID: 28192601
    [Abstract] [Full Text] [Related]

  • 18. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS).
    Almeida A, Fenaux P, List AF, Raza A, Platzbecker U, Santini V.
    Leuk Res; 2017 Jan 15; 52():50-57. PubMed ID: 27883945
    [Abstract] [Full Text] [Related]

  • 19. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
    Rojas SM, Díez-Campelo M, Luño E, Cabrero M, Pedro C, Calabuig M, Nomdedeu B, Cedena T, Arrizabalaga B, García M, Cerveró C, Collado R, Azaceta G, Ardanaz MT, Muñoz JA, Xicoy B, Rodríguez MJ, Bargay J, Morell MJ, Simiele A, del Cañizo C.
    Leuk Res; 2014 Mar 15; 38(3):304-9. PubMed ID: 24333115
    [Abstract] [Full Text] [Related]

  • 20. Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
    Giagounidis AA.
    Semin Hematol; 2012 Oct 15; 49(4):312-22. PubMed ID: 23079061
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.